Loading
Nanoparticle-based Drug Delivery / Nanoplatforms for Cancer Theranostics · Journal article
Biomolecules · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review examining bufalin's anticancer mechanisms and nanocarrier delivery strategies without reporting empirical efficacy data, comparative trials, or clinical outcomes. It identifies pharmacological rationale and development pathways but does not provide evidence of clinical benefit.
Narrative review.
Bufalin exerts pleiotropic antitumour effects by modulating oncogenic proteins and promoting their degradation Bufalin disrupts metabolic plasticity, induces multiple forms of regulated cell death, and counteracts therapeutic resistance Bufalin remodels the immunosuppressive tumour microenvironment
Poor aqueous solubility, rapid systemic clearance, narrow therapeutic window, and dose-limiting toxicity limit clinical application
The source did not state who this applies to in practice.
This is a narrative review synthesizing preclinical mechanistic evidence and nanocarrier design strategies for bufalin, with no clinical trials, efficacy data, or comparative outcomes reported.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Bufalin is a naturally occurring bufadienolide with broad-spectrum anticancer activity. Unlike conventional cytotoxic agents, bufalin exerts pleiotropic antitumour effects by directly modulating oncogenic proteins and promoting their degradation. It also disrupts metabolic plasticity, induces multiple forms of regulated cell death, counteracts therapeutic resistance, and remodels the immunosuppressive tumour microenvironment. However, the further application of bufalin is hindered by poor aqueous solubility, rapid systemic clearance, a narrow therapeutic window, and dose-limiting toxicity. Nanodrug delivery systems (NDDSs) offer a promising strategy for translating these interconnected pharmacological effects into spatially and temporally controlled therapeutic responses. This review summarises the distinctive anticancer mechanisms of bufalin and systematically evaluates the organic, inorganic, biomimetic, and hybrid nanocarriers developed for its delivery. Particular attention is given to tumour-responsive drug release, the targeting of cancer stem cells, the induction of ferroptosis and pyroptosis, metabolic modulation, sensitisation to phototherapy, and the activation of antitumour immunity. Finally, the major translational challenges are critically examined to inform the further rational development of bufalin-based nanomedicines.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.